Corneal neovascularization (CNV) is one of the main factors that induce blindness worldwide. However, current medical treatments cannot achieve non‐invasive and safe inhibition of CNV. A noninvasive photoacoustic imaging (PAI)‐guided method is purposed for the regression of CNV. PAI can monitor the oxygen saturation of cornea blood vessels through the endogenous contrast of hemoglobin and trace administrated drugs by themselves as exogenous contrast agents. An indocyanine green (ICG)‐based nanocomposite (R‐s‐ICG) is prepared for CNV treatment via eye drops and subconjunctival injections. It is demonstrated that R‐s‐ICG can enrich corneal tissues and pathological blood vessels rapidly with minor residua in normal eyeball tissues. Anti‐CNV treatment‐driven changes in the blood vessels are assessed by real‐time multimodal PAI in vivo, and then a safe laser irradiation strategy through the canthus is developed for phototherapy and gene therapy synergistic treatment. The treatment leads to the efficient inhibition of CNV with faint damages to normal tissues.

中文翻译：

---

多模态光声成像引导角膜新生血管的消退：一种无创且安全的策略。

角膜新生血管（CNV）是全世界导致失明的主要因素之一。然而，目前的医学治疗无法实现无创、安全的CNV抑制。无创光声成像 (PAI) 引导方法旨在消除 CNV。PAI通过血红蛋白的内源性对比和微量给药药物本身作为外源性对比剂来监测角膜血管的氧饱和度。制备了一种基于吲哚菁绿 (ICG) 的纳米复合材料 (R-s-ICG)，用于通过滴眼剂和结膜下注射进行 CNV 治疗。研究表明，R-s-ICG能够快速富集角膜组织和病理血管，且在正常眼球组织中残留极少。通过体内实时多模式 PAI 评估抗 CNV 治疗驱动的血管变化，然后开发通过眼角的安全激光照射策略，用于光疗和基因治疗的协同治疗。该治疗可有效抑制CNV，对正常组织造成轻微损害。